Pyxis Oncology Reports Encouraging Early Phase 1 Results for MICVO in Advanced Head and Neck Cancer

Pyxis Oncology, Inc. (NASDAQ: PYXS) has reported positive preliminary data from ongoing Phase 1 studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The early findings suggest clinical activity for MICVO both as a standalone therapy and in combination with pembrolizumab, a widely used immune checkpoint inhibitor.

Early Signals of Clinical Activity

In the Phase 1 monotherapy study, MICVO demonstrated meaningful tumor responses in heavily pretreated patients. At the evaluated dose level, patients achieved a confirmed objective response rate alongside a high rate of disease control, indicating that the therapy may help slow or reverse disease progression in this difficult-to-treat population.

In a separate Phase 1/2 study combining MICVO with pembrolizumab, higher response rates were observed across the initial dose levels evaluated. While patient numbers remain limited at this stage, the combination results point to potential synergy between MICVO’s targeted cytotoxic approach and immune checkpoint inhibition.

Manageable Safety Profile in Early Studies

Safety data from both studies indicate that MICVO has been generally manageable in early testing, with no treatment-related deaths reported to date. As with all early-stage trials, continued monitoring across larger patient groups will be important to better define tolerability and optimal dosing.

Targeted ADC Designed for Aggressive Tumors

MICVO is an investigational antibody-drug conjugate (ADC) that targets extradomain-B fibronectin, a protein commonly found in the tumor microenvironment of aggressive solid tumors. By delivering a cytotoxic payload directly to tumor-associated structures, MICVO is designed to maximize anti-tumor activity while limiting exposure to healthy tissue.

The therapy has received FDA Fast Track Designation for certain patients with recurrent or metastatic HNSCC, reflecting the unmet need in this setting and the potential of the approach.

Next Steps in Development

Pyxis Oncology plans to continue enrolling patients and generate additional data to further assess durability of response, safety, and dose optimization. Updated results from the monotherapy study are expected in 2026, along with additional data from the combination study in the second half of the year.

Broader Context

Treatment options for recurrent or metastatic head and neck cancer remain limited, particularly for patients who progress after standard therapies. Early clinical signals from new targeted approaches such as MICVO highlight ongoing efforts to expand the therapeutic landscape for this challenging disease.